SUMMARY Two-hundred and seventeen patients from a total population of 343 patients with arteriovenous malformations, were managed without surgery. Follow up was for a mean of 10-4 years. Using life survival analyses, there was a 42% risk of haemorrhage, 29% risk of death, 18% risk of epilepsy and a 27% risk of having a neurological handicap by 20 years after diagnosis in unoperated patients.
Arteriovenous malformations were first recognised by the ancient Egyptians in 1500 BC' and they were known to both ancient Roman and Arab worlds. 2 In Western medicine, Hunter described extracranial arteriovenous malformations in 1757, but it was not until 1863 that Virchov reported the pathological appearances of intracranial arteriovenous malformations. 3 The first clinical diagnosis of an arteriovenous malformation has been attributed to Steinhal in 1895. 3 Attempts at operative intervention began early, when in 1908 Krause tried unsuccessfully to ligate the feeding blood vessels of an arteriovenous malformation. 4 In 1928 Dandy5 reported in nine patients the effect of coagulation of blood vessels, or partial excision of the arteriovenous malformation, Cushing and Bailey6 discussed eight surgically managed patients. The introduction of cerebral angiography by Moniz in 1927 revolutionised the diagnosis and treatment of such lesions. Olivacrona and Ladenheim2 and Tonnis7 pioneered their surgical removal, demonstrating that excision could be accomplished without a prohibitive morbidity or mortality. This emphasis on surgical treatment for arteriovenous malformations has made it difficult to determine the natural history of the disorder.
Many centres have examined the results of surgery (table 1) . However, patients referred for treatment are frequently a selected population. Assessment of outcome after surgical treatment is rarely compared with conservative management especially in those presenting without haemorrhage. The number of untreated patients in reported series is usually too small to draw firm conclusions about the natural history of untreated arteriovenous malformations. There is generally a short follow up and only one study has used life survival analyses to assess outcome. The other studies have assessed risks as an absolute figure based on varying, often undefined, periods of follow up.
Before assessing the results of therapy the natural history of the condition must be determined. In particular the following questions require an answer: (1) What is the risk of subsequent haemorrhage? (2) What is the likelihood-of developing a late neurological deficit? (3) What is the risk of developing de novo epilepsy? (4) What is the risk of death? (5) What factors influence these risks?
We report a retrospective survey of the natural history of 217 patients who did not undergo any form of surgery or irradiation from an unselected Crawford, West, Chadwick, Shaw The majority of arteriovenous malformations were supratentorial (90%), the parietal lobe being most frequently These differences between patients managed conservatively and those treated surgically are important to bear in mind when attempting to apply the results of our follow up data to a less selected group of patients with arteriovenous malformations. The differences simply reflect surgical inaccessibility.
Follow up of unoperated patients Patients were followed up for a median of 9 years (mean 10-4 years) after diagnosis (range 1 to 35 years). Seventysix per cent of all our patients were traced to death or 1984 (table 10). In patients in whom follow up was not complete, data up to the last attendance are included in our results. Life-survival analyses allow for variable or incomplete follow up. Arteriovenous malformations of the brain Late epilepsy At the time of diagnosis 143 patients in the non-operated group had never had an epileptic seizure. At 20 years after diagnosis the risk of epilepsy had reached 18% (11% at 10 years) (fig 9) . In three patients this followed a late excision of the arteriovenous malformation. Nobody in whom the arteriovenous malformation was a coincidental finding, or who presented with a neurological deficit developed epilepsy within 20 years after diagnosis, compared with 22% (13% at 10 years) of those presenting with haemorrhage (p < 0.05).
Neither size nor depth of an arteriovenous malformation influenced the risk of developing de novo epilepsy. Women were at an increased risk of developing epilepsy compared to men (p < 0.02). Arteriovenous malformations involving the temporal lobe carried an increased risk (37%) of developing epilepsy compared with an overall risk for other sites of 16% (p < 0.14). This is not statistically significant but this might be due to the small number of DI100-U on90 untreated patients with temporal arteriovenous malformations which had not been treated surgically (19 patients).
Age at diagnosis was important. The younger the patient was at diagnosis, the more likely were they to develop epilepsy during follow up. Patients aged 10 to 19 had a 44% risk, those aged 20 to 29 a 31% risk of developing epilepsy during the next 20 years compared to a risk of about 6% for those over the age of 30. Nobody aged 60 years or over developed epilepsy during follow up (X2 for Trend p < 0.02).
Discussion
It is difficult to compare our data with previously reported studies because of the small numbers of untreated patients, short follow up and the surgical emphasis in the majority of other studies. Only five papers have more than fifty untreated patients'2-'6 and only two of these papers has median or average follow up of longer than five years.'3 '5 One other paper uses life survival statistics to analyse some of their results. '6 It is clear that the patients reported in studies of arteriovenous malformations vary considerably from study to study. This certainly reflects differing patterns of referral and variable bias in the proportion of patients offered surgical treatment. However the mode of presentation of our patients and characteristics of the arteriovenous malformations are similar to the majority of other large studies with less highly selected patients, in particular the Cooperative Study. '2 One fact seems to merit discussion concerning the relationship of the mode of presentation and characteristics of the arteriovenous malformation and that is that patients with small lesions were more likely to present with haemorrhage as a major diagnostic symptom (82%). This factor has been noted by many authors,'6 but this study shows that a small arteriovenous malformation does not subsequently carry a higher risk of haemorrhage. Graf suggested patients with small arteriovenous malformations Mortality during follow up from all causes (including initial mortality) by 20 years after diagnosis was 29%. Sixty-five per cent of these deaths were consequent upon the arteriovenous malformation and most commonly resulted from haemorrhage. Twenty-five per cent of patients who had a haemorrhage during follow up, died as a result of haemorrhage. This is similar to the mortality for a subsequent haemorrhage reported by Fults and Kelly,'5 and is probably a more accurate figure than that of 6% for mortality from initial presenting haemorrhage for the reasons discussed. It was difficult to identify any factors influencing mortality but parietal arteriovenous malformations may carry a reduced risk.
The majority of our patients were free from neurological deficit at the time of discharge from hospital, whilst 25% had a minor handicap. The majority, therefore, were independent and capable of work at the time of discharge and remained so during follow up.
The risk of developing epilepsy dunrng 20 year follow up was 18%. No other study appears to have looked at the development of de novo epilepsy in untreated patients. Patients with haemorrhage had the greatest risk of developing epilepsy (22%) and no patient who presented with either a neurological deficit or in whom the arteriovenous malformation was a coincidental finding, developed epilepsy during follow up. Arteriovenous malformations involving the temporal lobe had an increased risk (37%) compared to other lobes (16%). This is a retrospective study and therefore suffers from all the inherent problems of such studies. In particular, bias may have been introduced into treatment groups and accurate follow up data may be more difficult to obtain. However, because of the inclusion of a large population of medically managed patients it represents the first major study of arteriovenous malformations, offering some indication of their natural history. It also uses life survival statistics to try and quantify the risks of subsequent -neurological events.
Olivacrona wrote in 1948 "In the end, probably most, if not all, patients (with arteriovenous malformations) die of haemorrhage or are completely incapacitated".' The feeling is commonly shared by many neurosurgeons and neurologists and may be 9 influenced by their knowledge of the prognosis for aneurysmal subarachnoid haemorrhage. The natural history of patients suffering a haemorrhage from cerebral aneurysm is poor. Sixty per cent will be dead at 2 months and indeed of those who survive the first 24 hours 40% are dead within this time. 22 In those surviving 6 months the risk of rupture is between 3-4% per annum and carries a mortality of 67%. 23 Our study shows that the prognosis for patients with arteriovenous malformations is therefore much better and this fact must be considered in the overall management of a patient with an arteriovenous malformation.
